Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy

This publication has 10 references indexed in Scilit:

• Abacavir Substitution for Nucleoside Analogs in Patients With HIV LipoatrophyA Randomized Trial
  JAMA, 2002
• SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals
  HIV Research & Clinical Practice, 2002
• Lactacidemia in Asymptomatic HIV-Infected Subjects Receiving Nucleoside Reverse-Transcriptase Inhibitors
  Clinical Infectious Diseases, 2002
• Clinical Evaluation and Management of Metabolic and Morphologic Abnormalities Associated with Human Immunodeficiency Virus
  Clinical Infectious Diseases, 2002
• Body Habitus Changes and Metabolic Alterations in Protease Inhibitor–Naive HIV-1–Infected Patients Treated With Two Nucleoside Reverse Transcriptase Inhibitors
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
• Hyperlactatemia and Antiretroviral Therapy: The Swiss HIV Cohort Study
  Clinical Infectious Diseases, 2001
• Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
  AIDS, 2001
• The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
  AIDS, 1999
• Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
  The Lancet, 1999
• Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
  The Lancet, 1998